Interleukin-15 favors the expansion of central memory CD8+ T cells in ex vivo generated, antileukemia human cytotoxic T lymphocyte lines

Journal of Immunotherapy

Volumn 31, Issue 4, 2008, Pages 385-393

  Daudt, Liane ^a,b   MacCario, Rita ^a   Locatelli, Franco ^a   Turin, Ilaria ^a   Silla, Lucia ^b   Montini, Enrica ^a   Percivalle, Elena ^a   Giugliani, Roberto ^b   Avanzini, Maria Antonietta ^a   Moretta, Antonia ^a   Montagna, Daniela ^a,c  

^a UNIVERSITY OF PAVIA   (Italy)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Antileukemia CTLs; Antitumor adoptive immunotherapy; Common chains cytokines

Indexed keywords

CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; INTERLEUKIN 12; INTERLEUKIN 7; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL COMPARTMENTALIZATION; CELL EXPANSION; CELL LINE; CHILD; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EX VIVO STUDY; FEMALE; HUMAN; LYMPHOCYTE CULTURE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MEMORY CELL; PRIORITY JOURNAL;

ADOLESCENT; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-15; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 42649106831     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31816b1092     Document Type: Article

References (35)

1. Locatelli F, Burgio GR. Transplant of hematopoietic stem cells in childhood: where we are and where we are going. Haematologica. 1998;83:550-563.
2. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogeneous leukemia in marrow transplant patients. Blood. 1990;76:2462-2465.
3. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients. European Group for Blood and Marrow transplantation Working Party Chronic Leukemia. Blood. 1995;86:2041-2050.
4. Collins RHJ, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusion in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433-444.
5. van Rhee F, Lin F, Cullis JO, et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusion before the onset of hematological relapse. Blood. 1994;83:3377-3383.
6. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes costimulated by CD80 and interleukin-15. Nat Med. 2003;9:279-286.
7. Cooper LJN, Topp MN, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B- lineage leukemia effect. Blood. 2001;101:1637-1644.
8. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood. 1999;94: 1201-1208.
9. Locatelli F, Comoli P, Montagna D, et al. Innovative approaches of adoptive immune cell therapy in pediatric recipients of hematopoietic stem cell transplantation. Best Pract Clin Hematol. 2004;17:479-492.
10. Falkenburg JH, Willemze R. Minor histocompatibility antigens as targets of cellular immunotherapy in leukemia. Best Pract Clin Haematol. 2004;17:415-425.
11. Montagna D, Maccario R, Locatelli F, et al. Ex vivo priming for long-term maintenance of anti-leukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood. 2001;98:3359-3366.
12. Montagna D, Maccario R, Montini E, et al. Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukemia or myelodysplastic cells using both HLA-matched and partially matched donors. Exp Hematol. 2003;31:1031-1038.
13. Montagna D, Daudt LE, Locatelli F, et al. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction. Cancer Res. 2006;66:7310-7316.
14. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
15. + T cells clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Nat Acad Sci. 2002;99: 16168-16173.
16. Becknell B, Caligiuri M. Cancer T cell expands. Nat Med. 2003;9: 257-258.
17. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: functions, generation, and maintenance. Annu Rev Immunol. 2004;22:745-763.
18. Lodolce JP, Boone DL, Chai S, et al. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity. 1998;9:669-676.
19. + T cells in vitro. Blood. 2003;102:2541-2546.
20. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic is maintained by granulocyte/macrophage colony stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor-alfa. J Exp Med. 1992;176:1693-1702.
21. Montagna D, Locatelli F, Moretta A, et al. T lymphocyte of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation. Blood. 2004;103:4322-4329.
22. Montagna D, Schiavo R, Gibelli N, et al. Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. Int J Cancer. 2004;110:76-86.
23. + memory T-cell subsets in response to antigen or homeostatic cytokines. Blood. 2003;102: 4260-4266.
24. Iezzi G, Scheidegger D, Lanzavecchia A. Migration and function of antigen-primed nonpolarized T lymphocytes in vivo. J Exp Med. 2001;193:987-993.
25. + T cells. J Clin Invest. 2005; 115:1616-1626.
26. Wherry EJ, Teichhgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8T cell subsets. Nat Immunol. 2003;4:225-234.
27. Masopust D, Kaech SM, Wherry EJ, et al. The role of programming in memory T-cell development. Curr Opin Immunol. 2004;16: 217-225.
28. Schluns K, Lefrançois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol. 2003;3:269-279.
29. Schluns K, Williams K, Ma A, et al. Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8T cells. J Immunol. 2002;168:4827-4831.
30. + T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common γ-chain cytokines. J Immunol. 2003;171: 2134-2141.
31. Alpdogan O, Eng JM, Muriglan SJ, et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood. 2005;105:865-873.
32. + T cells. J Immunol. 2003;170: 5018-5026.
33. Weng NP, Liu K, Catalfamo M, et al. IL-15 is a growth factor and an activator of CD8 memory T cells. Ann NY Acad Sci. 2002;975: 46-56.
34. + T cells. Immunology. 2001; 103:281-290.
35. Cookson S, Reen D. IL-15 drives neonatal T cells to acquire CD56 and become activated effector cells. Blood. 2003;102:2195-2197.